BR112017014280A2 - métodos de transdiferenciação e métodos de uso da mesma - Google Patents
métodos de transdiferenciação e métodos de uso da mesmaInfo
- Publication number
- BR112017014280A2 BR112017014280A2 BR112017014280-5A BR112017014280A BR112017014280A2 BR 112017014280 A2 BR112017014280 A2 BR 112017014280A2 BR 112017014280 A BR112017014280 A BR 112017014280A BR 112017014280 A2 BR112017014280 A2 BR 112017014280A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- transdifferentiation
- insulin
- cells
- producing cells
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 6
- 102000004877 Insulin Human genes 0.000 abstract 3
- 108090001061 Insulin Proteins 0.000 abstract 3
- 229940125396 insulin Drugs 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098050P | 2014-12-30 | 2014-12-30 | |
| US62/098,050 | 2014-12-30 | ||
| PCT/IL2015/051267 WO2016108237A1 (en) | 2014-12-30 | 2015-12-30 | Methods of transdifferentiation and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017014280A2 true BR112017014280A2 (pt) | 2018-03-27 |
Family
ID=56284403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017014280-5A BR112017014280A2 (pt) | 2014-12-30 | 2015-12-30 | métodos de transdiferenciação e métodos de uso da mesma |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10179151B2 (enExample) |
| EP (2) | EP3698803B1 (enExample) |
| JP (1) | JP6817943B2 (enExample) |
| KR (1) | KR102487883B1 (enExample) |
| CN (1) | CN107750170B (enExample) |
| AU (1) | AU2015373129B2 (enExample) |
| BR (1) | BR112017014280A2 (enExample) |
| CA (1) | CA2972569A1 (enExample) |
| CO (1) | CO2017006937A2 (enExample) |
| EA (1) | EA035360B1 (enExample) |
| IL (1) | IL253234B (enExample) |
| MA (1) | MA41296A (enExample) |
| MX (1) | MX378321B (enExample) |
| SG (1) | SG11201705344VA (enExample) |
| WO (1) | WO2016108237A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2915143C (en) | 2013-06-13 | 2021-08-03 | Orgenesis Ltd. | Cell populations, methods of transdifferentiation and methods of use thereof |
| CA3059017C (en) | 2013-09-24 | 2021-05-25 | Giner Life Sciences, Inc. | System for gas treatment of a cell implant |
| MA41296A (fr) | 2014-12-30 | 2017-11-07 | Orgenesis Ltd | Procédés de transdifférenciation et procédés d'utilisation de ceux-ci |
| AU2017261267B2 (en) | 2016-05-05 | 2023-01-05 | Southwest Research Institute | Three-dimensional bioreactor for cell expansion and related applications |
| CA3043468C (en) | 2016-11-15 | 2021-06-22 | Giner Life Sciences, Inc. | Percutaneous gas diffusion device suitable for use with a subcutaneous implant |
| CN110831656A (zh) | 2017-05-04 | 2020-02-21 | 吉纳生命科学公司 | 稳健的可植入气体递送装置和方法、系统以及包括该装置的装置 |
| WO2018207179A1 (en) | 2017-05-08 | 2018-11-15 | Orgenesis Ltd. | Transdifferentiated cell populations and methods of use thereof |
| WO2018220621A2 (en) * | 2017-05-29 | 2018-12-06 | Orgenesis Ltd. | Vascular secretome, methods of making same, and methods of use thereof |
| WO2019073055A1 (en) | 2017-10-13 | 2019-04-18 | Imba - Institut Für Molekulare Biotechnologie Gmbh | ENHANCED REPROGRAMMING OF SOMATIC CELLS |
| EP3761999A4 (en) * | 2018-03-06 | 2021-11-17 | Orgenesis Ltd. | THREE-DIMENSIONAL GROUPS OF TRANSDIFFERENTIATED CELLS, ASSOCIATED COMPOSITIONS AND PROCESSES |
| US11149244B2 (en) | 2018-04-04 | 2021-10-19 | Southwest Research Institute | Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy |
| SG11202102986XA (en) | 2018-09-24 | 2021-04-29 | Southwest Res Inst | Three-dimensional bioreactors |
| EP3816276A1 (en) * | 2019-10-31 | 2021-05-05 | Unicyte Islet AG | Viable pancreatic islet-like cell structures and a method of preparing thereof |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| ATE141646T1 (de) | 1986-04-09 | 1996-09-15 | Genzyme Corp | Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US4992417A (en) | 1987-07-17 | 1991-02-12 | Mount Sinai School Of Medicine | Superactive human insulin analogues |
| US5082670A (en) | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5427940A (en) | 1991-06-03 | 1995-06-27 | Board Of Regents, The University Of Texas System | Engineered cells producing insulin in response to glucose |
| ES2157225T3 (es) | 1992-10-09 | 2001-08-16 | Advanced Tissue Sciences Inc | Celulas hepaticas de reserva. |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| EP0714438B1 (en) | 1993-08-16 | 2007-09-19 | RESEARCH DEVELOPMENT FOUNDATION (a Nevada corporation) | A novel homeobox factor which stimulates insulin expression in pancreatic islet cells |
| US5858973A (en) | 1994-02-23 | 1999-01-12 | The General Hospital Corporation | Transcription factor and uses therefor |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| US5849989A (en) | 1994-10-07 | 1998-12-15 | Ontogeny, Inc. | Insulin promoter factor, and uses related thereto |
| JP2000501290A (ja) | 1995-11-30 | 2000-02-08 | リサーチ ディベロップメント ファンデーション | ソマトスタチン及びインシュリン生成を刺激する化合物のスクリーニング・アッセイ |
| IL118376A0 (en) | 1996-05-22 | 1996-09-12 | Univ Ben Gurion | Polysaccharide sponges for cell culture and transplantation |
| JP2000513227A (ja) | 1996-06-24 | 2000-10-10 | ビーボウアールエックス ファーマスーティカルズ，インコーポレイテッド | インスリン分泌細胞の単離および増殖方法 |
| AU8777898A (en) | 1997-08-11 | 1999-03-01 | Chiron Corporation | Methods for genetically modifying t cells |
| CA2221195A1 (en) | 1997-11-14 | 1999-05-14 | Chantal E. Holy | Biodegradable polymer matrix |
| US6143293A (en) | 1998-03-26 | 2000-11-07 | Carnegie Mellon | Assembled scaffolds for three dimensional cell culturing and tissue generation |
| IL124957A0 (en) | 1998-06-16 | 1999-01-26 | Univ Ben Gurion | Active ingredient delivery systems and devices based on porous matrices |
| US6242666B1 (en) | 1998-12-16 | 2001-06-05 | The Scripps Research Institute | Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells |
| US6774120B1 (en) | 1999-06-01 | 2004-08-10 | Sarah Ferber | Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| US8778899B2 (en) | 1999-06-01 | 2014-07-15 | Sarah Ferber | Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| US6716824B1 (en) | 1999-10-22 | 2004-04-06 | F. Charles Brunicardi | Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy |
| US6759039B2 (en) | 2000-06-30 | 2004-07-06 | Amcyte, Inc. | Culturing pancreatic stem cells having a specified, intermediate stage of development |
| US7214371B1 (en) | 2000-09-01 | 2007-05-08 | Ben-Gurion University Of The Negev Research & Development Authority | Tissue engineered biografts for repair of damaged myocardium |
| US7524492B2 (en) | 2001-08-31 | 2009-04-28 | Joslin Diabetes Center, Inc. | Insulin related transcription factor and uses thereof |
| WO2003033697A1 (en) | 2001-10-18 | 2003-04-24 | Ixion Biotechnology, Inc. | Conversion of liver stem and progenitor cells to pancreatic functional cells |
| US7722894B2 (en) | 2001-10-22 | 2010-05-25 | Massachusetts Institute Of Technology | Biodegradable polymer |
| GB2415432B (en) | 2001-12-07 | 2006-09-06 | Geron Corp | Islet cells from human embryonic stem cells |
| AU2003217658A1 (en) * | 2002-02-22 | 2003-09-09 | University Of Florida | Cellular trans-differentiation |
| GB0206357D0 (en) | 2002-03-18 | 2002-05-01 | Univ Bath | Cells |
| JP4136434B2 (ja) | 2002-04-17 | 2008-08-20 | 進 清野 | インスリン産生細胞の誘導 |
| EP1507848A4 (en) | 2002-05-28 | 2005-11-23 | Becton Dickinson Co | EXPANSION AND TRANSDIFFERENCING OF HUMAN AZINUS CELLS |
| EP1620140B1 (en) | 2003-05-05 | 2013-10-09 | Ben-Gurion University Of The Negev Research And Development Authority | Injectable cross-linked polymeric preparations and uses thereof |
| JP2006525994A (ja) | 2003-05-12 | 2006-11-16 | サラ ファーバー， | 非膵島組織における調節された膵ホルモンの産生を誘導する方法 |
| WO2005005607A2 (en) | 2003-06-30 | 2005-01-20 | Lifescan, Inc. | Seeding pancreatic cells on porous matrices |
| CA2536067A1 (en) | 2003-08-27 | 2005-03-10 | Stemcells California, Inc. | Enriched pancreatic stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for these populations |
| CA2548464C (en) | 2003-12-09 | 2013-02-12 | Ben-Gurion University Of The Negev Research And Development Authority | Pulse-medium perfusion bioreactor with improved mass transport for multiple 3-d cell constructs |
| US20090239298A1 (en) | 2004-08-25 | 2009-09-24 | Technion Research & Development Foundation Ltd. | Methods of generating embryoid bodies using three dimensional scaffolds |
| EP1877446A1 (en) | 2005-03-02 | 2008-01-16 | Polyrizon Ltd. | Method for removal of toxins from mucosal membranes |
| EP1856246B1 (en) | 2005-03-07 | 2015-07-15 | Technion Research & Development Foundation Limited | Natural tissue-derived decellularized matrix and methods of generating and using same |
| US7517856B2 (en) | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
| CA2658180A1 (en) * | 2006-07-19 | 2008-01-31 | University Of Florida Research Foundation, Inc. | Compositions for reprogramming a cell and uses therefor |
| WO2008075339A2 (en) | 2006-12-18 | 2008-06-26 | Ben Gurion University Of The Negev | Scaffolding for tissue regeneration or repair |
| US20100226976A1 (en) | 2007-07-11 | 2010-09-09 | Marcelle Machluf | Encapsulated mesenchymal stem cells and uses thereof |
| IL187707A0 (en) | 2007-11-27 | 2008-11-03 | Univ Ben Gurion | Alginate scaffold in hepatectomy |
| WO2009126927A2 (en) * | 2008-04-11 | 2009-10-15 | Joslin Diabetes Center, Inc. | Methods of generating insulin-producing cells |
| WO2010022395A2 (en) * | 2008-08-22 | 2010-02-25 | President And Fellows Of Harvard College | Methods of reprogramming cells |
| JP5717253B2 (ja) | 2009-08-02 | 2015-05-13 | 学校法人東京女子医科大学 | 膵島細胞シート、製造方法及びその利用方法 |
| MX390753B (es) * | 2009-10-31 | 2025-03-21 | Genesis Tech Limited | Metodos para reprogramar celulas y usos de los mismos. |
| JP2011223993A (ja) | 2010-03-30 | 2011-11-10 | Kumamoto Univ | 幹細胞の分化誘導方法 |
| ES2986590T3 (es) | 2010-06-14 | 2024-11-12 | Scripps Research Inst | Reprogramación de células hacia un nuevo destino |
| US9499793B2 (en) | 2011-08-09 | 2016-11-22 | Yeda Research And Development Co. Ltd. | Downregulation of miR-7 for promotion of beta cell differentiation and insulin production |
| US9731046B2 (en) | 2012-02-21 | 2017-08-15 | Ben Gurion University Of The Negev Research And Development Authority | Hydrogel system comprising spatially separated bioactive polypeptides |
| EP2938347A4 (en) | 2012-12-30 | 2016-08-10 | Hadasit Med Res Service | USE OF ALGINATE COMPOSITIONS TO PREVENT OR PREVENT LIVER DAMAGE THROUGH HEPATOTOXIC |
| EP2994528B1 (en) | 2013-05-08 | 2023-11-08 | ProKidney | Organoids comprising isolated renal cells and uses thereof |
| CA2915143C (en) * | 2013-06-13 | 2021-08-03 | Orgenesis Ltd. | Cell populations, methods of transdifferentiation and methods of use thereof |
| EP3107549B1 (en) | 2014-02-20 | 2020-07-01 | B.G. Negev Technologies and Applications Ltd. | Anionic polyplexes for use in the delivery of nucleic acids |
| WO2015184313A1 (en) | 2014-05-30 | 2015-12-03 | Secant Medical, Inc. | Water-mediated preparations of polymeric materials |
| US10208133B2 (en) | 2014-06-02 | 2019-02-19 | B.G. Negev Technologies And Applications Ltd. | Site-selective modification of polysaccharides and applications thereof |
| MA41296A (fr) | 2014-12-30 | 2017-11-07 | Orgenesis Ltd | Procédés de transdifférenciation et procédés d'utilisation de ceux-ci |
| EP3400074B1 (en) | 2016-01-07 | 2021-10-20 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | Compositions for generating immunotolerant responses |
| WO2017175229A1 (en) | 2016-04-07 | 2017-10-12 | B.G. Negev Technologies And Applications Ltd. | Polysaccharide compositions and uses thereof |
| US20170290954A1 (en) | 2016-04-07 | 2017-10-12 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Compositions and methods for treating spinal cord injury |
| WO2018207179A1 (en) | 2017-05-08 | 2018-11-15 | Orgenesis Ltd. | Transdifferentiated cell populations and methods of use thereof |
-
2015
- 2015-12-29 MA MA041296A patent/MA41296A/fr unknown
- 2015-12-30 SG SG11201705344VA patent/SG11201705344VA/en unknown
- 2015-12-30 EP EP20156154.5A patent/EP3698803B1/en active Active
- 2015-12-30 US US14/983,657 patent/US10179151B2/en active Active
- 2015-12-30 BR BR112017014280-5A patent/BR112017014280A2/pt not_active Application Discontinuation
- 2015-12-30 KR KR1020177021293A patent/KR102487883B1/ko active Active
- 2015-12-30 EP EP15875374.9A patent/EP3240576B1/en active Active
- 2015-12-30 WO PCT/IL2015/051267 patent/WO2016108237A1/en not_active Ceased
- 2015-12-30 EA EA201791508A patent/EA035360B1/ru unknown
- 2015-12-30 MX MX2017008669A patent/MX378321B/es unknown
- 2015-12-30 CN CN201580077116.8A patent/CN107750170B/zh not_active Expired - Fee Related
- 2015-12-30 CA CA2972569A patent/CA2972569A1/en active Pending
- 2015-12-30 JP JP2017535829A patent/JP6817943B2/ja not_active Expired - Fee Related
- 2015-12-30 AU AU2015373129A patent/AU2015373129B2/en not_active Ceased
-
2017
- 2017-06-29 IL IL253234A patent/IL253234B/en active IP Right Grant
- 2017-07-11 CO CONC2017/0006937A patent/CO2017006937A2/es unknown
-
2018
- 2018-11-29 US US16/203,654 patent/US10668107B2/en not_active Expired - Fee Related
-
2020
- 2020-04-01 US US16/836,967 patent/US11617769B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX378321B (es) | 2025-03-10 |
| IL253234A0 (en) | 2017-08-31 |
| CO2017006937A2 (es) | 2017-10-20 |
| WO2016108237A1 (en) | 2016-07-07 |
| CN107750170A (zh) | 2018-03-02 |
| KR20170102308A (ko) | 2017-09-08 |
| US20200297777A1 (en) | 2020-09-24 |
| US20160220616A1 (en) | 2016-08-04 |
| JP2018502574A (ja) | 2018-02-01 |
| EA201791508A1 (ru) | 2018-05-31 |
| IL253234B (en) | 2020-04-30 |
| EA035360B1 (ru) | 2020-06-02 |
| EP3698803A1 (en) | 2020-08-26 |
| MX2017008669A (es) | 2018-02-16 |
| EP3240576B1 (en) | 2020-03-04 |
| EP3240576A4 (en) | 2018-06-20 |
| EP3698803B1 (en) | 2023-03-08 |
| AU2015373129A1 (en) | 2017-08-03 |
| CA2972569A1 (en) | 2016-07-07 |
| SG11201705344VA (en) | 2017-07-28 |
| US10668107B2 (en) | 2020-06-02 |
| AU2015373129B2 (en) | 2021-07-15 |
| KR102487883B1 (ko) | 2023-01-11 |
| EP3240576A1 (en) | 2017-11-08 |
| JP6817943B2 (ja) | 2021-01-20 |
| US20190134097A1 (en) | 2019-05-09 |
| MA41296A (fr) | 2017-11-07 |
| US11617769B2 (en) | 2023-04-04 |
| US10179151B2 (en) | 2019-01-15 |
| CN107750170B (zh) | 2021-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017014280A2 (pt) | métodos de transdiferenciação e métodos de uso da mesma | |
| BR112017008284A2 (pt) | bifidobactérias ativadas e métodos para uso das mesmas | |
| SV2018005709A (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| DOP2017000025A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| MX2021006734A (es) | Metodo para tratar el cancer. | |
| BR112017025045A2 (pt) | plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600 | |
| ZA201608077B (en) | Combination, composition, and method of administering the combination or composition to animals | |
| MX387487B (es) | Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton. | |
| DK3212208T3 (da) | Anvendelse af l. reuteri til forebyggelse eller behandling af mikrobiotadysbiose tidligt i livet | |
| MX2016013963A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| MX374399B (es) | Composiciones y sus usos para tratar y prevenir la enfermedad de huntington. | |
| AR099564A1 (es) | Composiciones fraguables y sus usos | |
| AR100498A1 (es) | Mejora en la reducción de la fricción | |
| CL2016000378A1 (es) | Composiciones y métodos terapéuticos para la regresión acelerada de placa | |
| EP3233091A4 (en) | Hypochlorous acid formulations and methods for treating skin conditions | |
| BR112018003864A2 (pt) | método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido | |
| CL2016001076A1 (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis. | |
| BR112016028910A2 (pt) | sistema e método para ancoragem de válvula cardíaca | |
| EP3321259A4 (en) | NEW PYRAZINE DERIVATIVE AND METHOD OF MANUFACTURE AND MEDICAL USE THEREOF | |
| BR112017005428A2 (pt) | método para tratar uma formação subterrânea, sistema para realizar o método de tratamento de uma formação subterrânea, sistema, composição para o tratamento de uma formação subterrânea e método de preparar uma composição para o tratamento de uma formação subterrânea | |
| MX373176B (es) | Donadores de nitroxilo con indice terapeutico mejorado. | |
| BR112018075162A2 (pt) | composições para higiene bucal | |
| CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
| MX2016010328A (es) | Tratamiento con halogeno de ataque cardiaco y lesion isquemica. | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: TEL HASHOMER-MEDICAL RESEARCH, INFRASTRUCTURE AND SERVICES LTD (IL) ; ORGENESIS LTD. (IL) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |